Catalyst Pharmaceuticals, INC Form 4 insider transactions

Catalyst Pharmaceuticals' Chairman, Patrick J. McEnany, sold a total of 492,000 shares after exercising options, while remaining the largest individual shareholder.

Patrick McEnany, a Director and Chairman of the Board at Catalyst Pharmaceuticals, donated 5,100 shares of common stock to the Baptist Health South Florida Foundation.

Director David S. Tierney of Catalyst Pharmaceuticals, Inc. reports the sale of 15,000 shares of common stock on August 21, 2024.

Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, sold 150,000 shares of common stock on August 20, 2024, for personal reasons.

Patrick McEnany, a Director at Catalyst Pharmaceuticals, gifted 45,000 shares of common stock to the Baptist Health South Florida Foundation on August 15, 2024.

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, sold shares on August 9, 2024, following the exercise of stock options.

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold 100,000 shares of common stock on August 9, 2024.

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, sold 7,541 shares of common stock at $16.07 per share on June 7, 2024.

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold 80,000 shares of common stock on June 5, 2024, to cover the exercise price and tax obligations related to stock options.

Richard Daly, CEO of Catalyst Pharmaceuticals, exercised stock options and sold a portion of the acquired shares on June 4, 2024.

Director Molly Harper sold 5,333 shares of Catalyst Pharmaceuticals (CPRX) common stock at an average price of $16.304 per share on June 3, 2024, for personal reasons.

David S. Tierney, a director at Catalyst Pharmaceuticals, sold 25,000 shares of common stock on April 8, 2024, to cover a personal tax liability.

Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, sold 25,000 shares of common stock on March 27, 2024, to cover a personal tax liability.